SCHEMBL18636426

SCHEMBL18636426

Nc1ncnn2c(C3O[C@H](COCc4ccccc4)[C@@H](OCc4ccccc4)[C@H]3F)ccc12

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PDE2A O00408 2/20 0.49
▸ HTR1A P08908 1/20 0.39
▸ HSPA5 P11021 1/20 0.37
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ PTPN1 P18031 6/20 0.36
▸ CDC25B P30305 6/20 0.36
▸ GJB2 P29033 2/20 0.35
▸ PTPN2 P17706 2/20 0.35
▸ PTPN6 P29350 2/20 0.35
▸ PTPN11 Q06124 2/20 0.35
▸ SSTR1 P30872 1/20 0.34
▸ SSTR2 P30874 1/20 0.34
▸ SSTR4 P31391 1/20 0.34
▸ SSTR3 P32745 1/20 0.34
▸ SSTR5 P35346 1/20 0.34
▸ NT5E P21589 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19227796 1.00 PDE2A (0.49) PDE2AHTR1AHSPA5CA1CA2
SCHEMBL17106820 0.91 HTR1A (0.43) PDE2AHTR1AHSPA5CA1CA2
SCHEMBL25598746 0.91 HTR1A (0.43) PDE2AHTR1AHSPA5CA1CA2
SCHEMBL17106818 0.91 HTR1A (0.43) PDE2AHTR1AHSPA5CA1CA2
SCHEMBL22434801 0.87 PDE2A (0.39) PDE2AHTR1AHSPA5CA1CA2
SCHEMBL18787319 0.86 PDE2A (0.50) PDE2AHTR1AHSPA5CA1CA2
SCHEMBL16701323 0.84 PDE2A (0.48) PDE2AHTR1AHSPA5CA1CA2
SCHEMBL19101786 0.84 PDE2A (0.48) PDE2AHTR1AHSPA5CA1CA2
SCHEMBL4973436 0.81 DOT1L (0.33) PDE2AGJB2
SCHEMBL4971379 0.81 DOT1L (0.33) PDE2AGJB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230125751-A1 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2023-04-27 — — US disclosed
US-20230027727-A1 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2023-01-26 — — US disclosed
US-11382926-B2 Methods for treating Arenaviridae and Coronaviridae virus infections GILEAD SCIENCES, INC. (US) 2022-07-12 — — US disclosed
US-20210393659-A1 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2021-12-23 — — US disclosed
EP-3212175-B1 METHODS FOR THE PREPARATION OF RIBOSIDES GILEAD SCIENCES INC (US) 2021-11-24 — — EP disclosed
US-20210061806-A1 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2021-03-04 — — US disclosed
EP-3785717-A1 METHODS FOR TREATING CORONAVIRIDAE INFECTIONS Gilead Sciences, Inc. (US) 2021-03-03 — — EP disclosed
US-10696679-B2 Methods and compounds for treating paramyxoviridae virus infections GILEAD SCIENCES, INC. (US) 2020-06-30 — — US disclosed
US-10695361-B2 Methods for treating arenaviridae and coronaviridae virus infections GILEAD SCIENCES, INC. (US) 2020-06-30 — — US disclosed
US-20190255085-A1 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2019-08-22 — — US disclosed
US-10251904-B2 Methods for treating arenaviridae and coronaviridae virus infections GILEAD SCIENCES, INC. (US) 2019-04-09 — — US disclosed
US-20190055251-A1 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2019-02-21 — — US disclosed
US-20170226140-A1 2' FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. 2017-08-10 — — US disclosed
US-20170071964-A1 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2017-03-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210061806-A1 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS PNP, RPIA, HPRT1 PDE2A 1863/4885HTR1A 2570/4885HSPA5 4656/4885
US-20170226140-A1 2' FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT PNP, NUDT1, NSUN2 PDE2A 1006/4885HTR1A 2056/4885HSPA5 4597/4885
US-10696679-B2 Methods and compounds for treating paramyxoviridae virus infections PNP, RPIA, HPRT1 PDE2A 1863/4885HTR1A 2570/4885HSPA5 4656/4885
US-10251904-B2 Methods for treating arenaviridae and coronaviridae virus infections ACE, PNP, ACE2 PDE2A 3746/4885HTR1A 2011/4885HSPA5 3890/4885
US-20190055251-A1 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS PNP, RPIA, HPRT1 PDE2A 1863/4885HTR1A 2570/4885HSPA5 4656/4885
US-10695361-B2 Methods for treating arenaviridae and coronaviridae virus infections ACE, PNP, ACE2 PDE2A 3746/4885HTR1A 2011/4885HSPA5 3890/4885
US-11382926-B2 Methods for treating Arenaviridae and Coronaviridae virus infections ACE, PNP, ACE2 PDE2A 3746/4885HTR1A 2011/4885HSPA5 3890/4885
US-20230125751-A1 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS PNP, RPIA, HPRT1 PDE2A 1863/4885HTR1A 2570/4885HSPA5 4656/4885
US-20190255085-A1 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS ACE, PNP, ACE2 PDE2A 3746/4885HTR1A 2011/4885HSPA5 3890/4885
US-20210393659-A1 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS ACE, PNP, ACE2 PDE2A 3746/4885HTR1A 2011/4885HSPA5 3890/4885
US-20170071964-A1 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS ACE, PNP, ACE2 PDE2A 3746/4885HTR1A 2011/4885HSPA5 3890/4885
US-20230027727-A1 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS PNP, ACE, ACE2 PDE2A 3717/4885HTR1A 1956/4885HSPA5 3887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback